featured
Once-Daily Risdiplam Shows Benefit for SMA Types 2 and 3
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
Lancet Neurol 2022 Jan 01;21(1)42-52, E Mercuri, N Deconinck, ES Mazzone, A Nascimento, M Oskoui, K Saito, C Vuillerot, G Baranello, O Boespflug-Tanguy, N Goemans, J Kirschner, A Kostera-Pruszczyk, L Servais, M Gerber, K Gorni, O Khwaja, H Kletzl, RS Scalco, H Staunton, WY Yeung, C Martin, P Fontoura, JW DayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.